News

“We believe the Kiadis ‘off the shelf’ K-NK cell technology platform will have broad application against liquid and solid tumors, and create synergies with Sanofi’s emerging immuno-oncology pipeline,

The deal has a total enterprise value of around $368m. Based in Cambridge, Horizon Discovery offers CRISPR and RNAi reagents, cell models, cell engineering and base editing solutions

The parties have now obtained all required antitrust clearances for the proposed transaction. The combination will be effected through a Reverse Morris Trust transaction, pursuant to which Upjohn

Adakveo can be provided as an add-on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate, said Novartis. Adakveo attaches to

The primary goal of this Phase 3 randomized, double-blind, multicenter, placebo-controlled clinical trial is to determine if lenzilumab can help hospitalized patients with COVID-19 recover faster. As many

Under the deal, Cheplapharm will purchase Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide), which is marketed in around 70 countries across

This approval makes Zejula the only PARP inhibitor approved in the European Union for use as a monotherapy for patients with advanced ovarian cancer, regardless of their biomarker

Lenzilumab is the Company’s lead product candidate and proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody designed to optimize antibody properties. ACTIV-5/BET, which is being conducted

Under the deal, Vedere shareholders have secured $150m upfront payment and also eligible to secure up to $130m in milestone payments. Vedere Bio has an advanced platform for